Atropine
Atropine 1% · ophthalmic solution
Mydriatics/Cycloplegics
Approved uses
Cycloplegia and mydriasis
1 drop to the conjunctival cul-de-sac 40 minutes before intended maximal dilation, from 3 months of age; may be repeated up to twice daily from 3 years of age.
Dilation begins within 40 minutes, peaks at about 2 hours, and can persist up to 2 weeks.
Penalization of the healthy eye in amblyopia
1 drop to the conjunctival cul-de-sac of the healthy eye, from 3 months of age; may be repeated up to twice daily as needed from 3 years of age, and limited to one drop per eye per day under 3 years.
Acuity gain equals patching, and weekend-only dosing works as well as daily dosing.
OFF-LABELNot in the FDA label for this product
Myopia progression control in children
1 drop nightly OU of 0.01%, 0.025%, or 0.05% (LAMP) or of 0.01%, 0.1%, or 0.5% (ATOM2); these are prepared low concentrations, not this 1% product.
RCTs · n=438 · US trial null
LAMP randomized 438 children aged 4 to 12 to nightly 0.05%, 0.025%, 0.01%, or placebo, with 1-year spherical equivalent change of -0.27, -0.46, -0.59, and -0.81 D (P < 0.001) and 0.05% still the optimal concentration at 3 years in that Chinese cohort. ATOM2 randomized 400 children aged 6 to 12 to nightly 0.5%, 0.1%, or 0.01% for 2 years (progression -0.30, -0.38, and -0.49 D, differences the authors judged clinically insignificant), and the 0.01% arm had the smallest rebound in the washout year. A US randomized placebo-controlled trial of 0.01% in 187 children found no effect at 24 months (adjusted difference -0.02 D, 95% CI -0.19 to +0.15 D), so benefit at the lowest concentration is not established in every population.
Contraindications
Previous hypersensitivity or known allergic reaction to any ingredient of the formulation (because it may recur)
1% solution (10 mg/mL atropine sulfate, 8.3 mg/mL base), 2 mL, 5 mL, 15 mL dropper bottles
Reversible antagonist of muscarine-like actions of acetylcholine, relatively selective for muscarinic receptors and not distinguishing among the M1, M2, and M3 subgroups; potency at nicotinic receptors is much lower and actions at non-muscarinic receptors are generally undetectable clinically. Blocking muscarinic activation of the pupillary constrictor leaves sympathetic dilator tone unopposed, giving mydriasis, and weakening ciliary muscle contraction gives cycloplegia with loss of accommodation for near.
Warnings & Precautions
- Photophobia and blurred vision: Pupil unresponsiveness and cycloplegia may last up to 2 weeks.
- Blood pressure elevation: Reported after conjunctival instillation of recommended doses of the 1% solution.
- Hypertensive crisis: Concurrent use with MAO inhibitors is generally not recommended, given the potential to precipitate hypertensive crisis.
- Overdosage: In pediatric populations, 10 mg or less may be fatal; physostigmine abolishes delirium and coma but is rapidly destroyed, so the patient may again lapse into coma after one to two hours and repeated doses may be required.
Common Side Effects
The most common adverse reactions reported are eye pain and stinging on administration, blurred vision, photophobia, decreased lacrimation, and increased heart rate and blood pressure. Superficial keratitis is another commonly occurring ocular adverse reaction. Allergic reactions such as papillary conjunctivitis, contact dermatitis, and lid edema may also occur less commonly. Systemic adverse events reported include dryness of skin, mouth, and throat, restlessness, irritability or delirium, tachycardia, and flushed skin of the face and neck.
Pregnancy: No adequate and well-controlled studies in pregnant women and no animal development or reproduction studies; use only if the potential benefit justifies the potential fetal risk.
Lactation: Traces have been found in human milk after administration of the injectable solution, and because some systemic absorption occurs from topical dosing, use caution in a nursing woman.
Not recommended under 3 months; under 3 years limit to one drop per eye per day.